Physician profile
Daniel Jonas
NPI 1720519598
$1,192.33
in general payments reported to CMS, 2019-2025
14 companies · $816 in 2025
The $816 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $27.43 · 2024: $348 · 2025: $816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,164.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $392.30 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $151.70 | 2024-2025 | Entyvio, Eohilia |
| Madrigal Pharmaceuticals | $119.64 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $109.52 | 2024-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $76.41 | 2024-2025 | Dupixent |
| Qol Medical, LLC | $76.24 | 2024-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $60.26 | 2025 | |
| Celltrion USA INC. | $58.67 | 2025 | Vegzelma |
| Phathom Pharmaceuticals, INC. | $37.01 | 2025 | Voquezna |
| Ardelyx, INC. | $30.09 | 2025 | Ibsrela |
| Medtronic, INC. | $27.43 | 2022 | |
| Pfizer INC. | $22.60 | 2025 | |
| Vivus LLC | $15.78 | 2025 | Qsymia |
| Sandoz INC. | $14.68 | 2024 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Jonas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.